Services – Thyrocare

[vc_row disable_element=”yes”][vc_column][rev_slider_vc alias=”dentist-home”][/vc_column][/vc_row][vc_row disable_element=”yes” css=”.vc_custom_1574233541676{padding-top: 80px !important;padding-bottom: 72px !important;background-color: #ffffff !important;}”][vc_column][vc_row_inner row_content_width=”grid”][vc_column_inner offset=”vc_col-md-4″][vc_single_image image=”6153″ img_size=”full”][vc_empty_space height=”13px”][vc_column_text]

Adhesive Dentistry

Specialty Clinics

Maxillofacial Care

[/vc_column_text][vc_column_text]Ut wisi enim ad minim veniam, quis laore est usus legentis in iis qui facit eorum nostrud exerci tation ulm hedi corper turet suscipit lobortis nisl aliquip[/vc_column_text][vc_empty_space height=”15px”][mkdf_button type=”simple” text=”Read More” target=”_self” icon_pack=”” font_weight=”” link=”http://mediclinic.mikado-themes.com/working-hours/” color=”#333333″][vc_empty_space height=”40px”][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row row_content_width=”grid” css=”.vc_custom_1574236875487{padding-top: 70px !important;padding-bottom: 120px !important;background-color: #fafafa !important;}” el_id=”#services”][vc_column][mkdf_elements_holder number_of_columns=”one-column” switch_to_one_column=”” alignment_one_column=””][mkdf_elements_holder_item item_padding=”0px 20%” item_padding_1280_1600=”0px 20%” item_padding_1024_1280=”0px 20%” item_padding_768_1024=”0px 8%” item_padding_600_768=”0px” item_padding_480_600=”0px” item_padding_480=”0px”][mkdf_section_title type=”standard” position=”center” title_tag=”” disable_break_words=”no” title=”Genetic Test”][/mkdf_elements_holder_item][/mkdf_elements_holder][/vc_column][/vc_row][vc_row row_content_width=”grid”][vc_column][mkdf_tabs type=”standard”][mkdf_tabs_item tab_title=”Exacta”][vc_column_text css=”.vc_custom_1590683901520{margin-top: -20px !important;}”]

Exacta

[/vc_column_text][vc_empty_space height=”30px”][vc_single_image image=”11532″ alignment=”center” css=”.vc_custom_1590683895473{padding-top: 15px !important;}”][vc_column_text]

INTRODUCTION

Cancer is a disease of the genes. Like every human being, each person’s cancer is unique. Unfortunately, conventional ‘Standard of Care’ approach does not take into consideration the overall genetic architecture of a particular patient’s tumor and consequently patients usually suffer due to failed therapies or aggressive relapse. It is thus imperative that the genetic architecture of the tumor is studied comprehensively before deciding the treatment plan, especially where treatments are failing or even the Standard of Care options are unsatisfactory.

About Exacta

Exacta^® is an intensive and in depth tumor gene expression analysis. It analyses 100s of millions of data points at the molecular level to reveal all possible targets for precision drugs. Exacta® is one of the most powerful tumor investigation and is an extreme analytical tool that reveals the driven mutations and pathways driving a person’s cancer. Exacta is best molecular analysis for difficult cancers.

Features of Exacta

Determines deepest genetic secrets of an individual patient’s cancer.
Accurate, multi-coordinate analysis of all 22,000 genes in the cancer genome.
Reaches the depths of cancer’s mechanism through 100’s of millions of data points.
Reveals mutations and pathways that are propelling a particular cancer in an individual.
Enables a highly sophisticated treatment strategy beyond conventional perspective.

[/vc_column_text][/mkdf_tabs_item][mkdf_tabs_item tab_title=”TruBlood”][vc_column_text css=”.vc_custom_1590683880769{margin-top: -20px !important;}”]

TruBlood

[/vc_column_text][vc_empty_space height=”30px”][vc_single_image image=”9970″ img_size=”full” alignment=”center” css=”.vc_custom_1590683875652{padding-top: 15px !important;}”][vc_column_text]

INTRODUCTION

Trublood^TM is a revolutionary Encyclopedic Liquid Biopsy that aims to substitute invasive tissue extraction for all cancers. Conceptualized and developed by Datar Cancer Genetics Ltd by efforts of several dozen scientist working relentlessly for the last five years, Trublood has been validated over thousands of samples – both from asymptomatic individuals and cancer patients.

[/vc_column_text][vc_column_text]

trublood™ is a non-Invasive, blood-based investigation for symotomatlc individuals who have been advised a biopsy to check for malignancy.
trublood™ can also be considered for patients where an invasive biopsy has been inconclusive or inconsistent with clinical observations.
trublood™ is also recommended in case of suspected metastatic relapse to rule out new primary.
trublood™ utilises a proprietary technique to capture Circulating Tumor Cells from the blood with extremely high efficiency as well as permits Genomic Analysis of Circulating Tumor DNA.

Diagnostic determination i.e. malignant I non-malignant
Organ of origin confirmation
Classification viz. Adenocarcinoma I Squamous cell carcinoma etc.
Sub-classification viz. Hormone Receptor +ve I -ve etc.
lmmuno-cytochemistry for treatment guidance
FISH
ctDNA (Circulating Tumor DNA)

[/vc_column_text][/mkdf_tabs_item][mkdf_tabs_item tab_title=”Cancer Track”][vc_column_text css=”.vc_custom_1590683856738{margin-top: -20px !important;}”]

Cancer Track

[/vc_column_text][vc_single_image image=”11536″ alignment=”center” css=”.vc_custom_1590683868479{padding-top: 15px !important;}”][vc_column_text]

INTRODUCTION

Till now, tissue biopsies represent the standard test of tumor diagnosis. Unfortunately tissue biopsy only reflects a single point in time of a single site of the tumor. This inadequacy for the comprehensive characterization of a patient’s tumor can be overcome with liquid biopsy.

We at Datar Cancer Genetics Limited offer you Cancertrack^TM which is a non-invasive blood test that detects cancer cells and their fragments with ultra-high precision, specificity and reliability. This test checks for cancerous cells / cancer cell fragments to monitor the disease / recurrence or to keep an eye on changes in the tumor characteristics, as often as necessary, without the cost, risk and consequences of radiation from scans, hospitalization, anesthesia or painful surgical biopsies.

Utilizes multi-coordinate and multidimensional probes to track down the tiniest of fragments of cells / DNA / RNA released by cancer cells in the patient’s blood
Possesses unique and unprecedented capability to detect cancerous activity
Enables a rapid response in real-time to the dynamic molecular profile of a patient’s cancer
Safe, sure, simple and cost-effective
Non-invasive blood test
Not dependent on availability of tissue
Rapid lab result
Tests all active disease sites
Limits of detection is 0.1% MAF
Far more powerful than conventional biopsy
100% coverage of NCCN biomarkers
All clinically significant findings re-confirmed by separate platform

[/vc_column_text][/mkdf_tabs_item][mkdf_tabs_item tab_title=”Gliotrack”][vc_column_text]

Gliotrack

[/vc_column_text][vc_single_image image=”11537″ alignment=”center”][vc_column_text]

INTRODUCTION

The need for minimally invasive approaches for diagnosis and monitoring of brain tumors for both primary and metastatic disease has prompted the emergence of liquid biopsy. Liquid biopsy offers technologic advancements for the measurement of Airculating tumor biomarkers with continued refinements in standardization and improved signal detection. Datar Cancer Genetics Limited is committed to growing this area of molecular analysis.

Gliotrack™ detects tumor biomarkers like cell free tumor DNA (ctDNA), mRNA and microRNA released by the tumor cells in peripheral blood of the patient. Cell free tumor DNA (ctDNA) is released by the dying tumor cells whereas mRNA and microRNA are actively secreted in the form of exosomes by the live tumor cells.

Several circulating biomarkers in the peripheral blood such as circulating tumor cells, tumor derived cell free DNA (ctDNA), tumor derived micro-vesicles called exosomes are considered in recent years for their use in non-invasive assessment of tumor derived molecular artifacts due to their high sensitivity and specificity. The analysis of circulating, cell free DNA is one of the most promising technical advances to provide an alternative to tumor biopsy.

Patients with suspected glioma on MRI.
Patients with glioma who are unfit for biopsy e.g. Diffuse intrinsic pontine glioma or associated comorbidities.
Patients with inadequate tissue sample for molecular stratification / prognostication.
Diagnosed glioma patients – to select optimum therapy or to monitor therapy response .
Patients on treatment – to distinguish true disease progression from treatment associated changes like radiation necrosis and to monitor residual disease.
Patients in remission – to detect recurrence at the earliest.

[/vc_column_text][/mkdf_tabs_item][mkdf_tabs_item tab_title=”Liquid Biopsy For Lung Cancer”][vc_column_text]

Liquid Biopsy For Lung Cancer

[/vc_column_text][vc_single_image image=”11536″ alignment=”center”][vc_column_text]

INTRODUCTION

Liquid biopsy, a noninvasive alternative to tissue biopsy, provides real-time monitoring of lung cancer via more frequent analysis of circulating biomarkers, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).

Datar Cancer Genetics Limited offers a more comprehensive picture of the disease that may reflect the status of the disease better and thereby contribute to more personalized treatment than tissue analysis.

Non-invasive biopsy for lung cancer mutation analysis
Inadequacy of tumor tissue is no longer a problem for targeted therapy selection
Patients unfit for invasive biopsy can still avail benefit of targeted therapies
Addresses problem of tumor heterogeneity
Helps in real-time disease monitoring and tumor evolution tracking
Therapy failure, due to acquired resistance mutations, can be detected prior to clinical/radiological disease progression
Gives information about tumor burden and molecular residual disease
Helps to know presence of acquired resistance mutations
High sensitivity (96.4%) and specificity (100%)
ASCO 2016 endorsed a liquid biopsy for tumor mutation analysis with respect

[/vc_column_text][/mkdf_tabs_item][mkdf_tabs_item tab_title=”Geneshield”][vc_column_text css=”.vc_custom_1590680888997{margin-top: -20px !important;}”]

Geneshield

[/vc_column_text][vc_single_image image=”11535″ alignment=”center”][vc_column_text]

INTRODUCTION

Pharmacokinetics and pharmacodynamics of a drug depends on complex processes that are coded by different genes influencing drug transport, metabolism, and mechanism of action. When gene mutation and polymorphisms occur, the drug affinity towards metabolic activity or receptors also differs. More than 75% of the metabolic interactions of drugs are mediated through Cytochrome P450. We analyse the gene variant related to the ubiquitous P450 group of genes besides other relevant alleles. Among the various factors that influence expression and function of the enzymes to predict pharmacokinetics and drug response, monogenic polymorphisms play a major part in the variability of enzymes.

Drugs are a significant cause of morbidity and mortality, induced by Adverse Drug Reactions (ADRs). Although, till recently, the efficacy of drugs and their possible reactions were largely speculative for a given individual, recent developments in genetic sequencing technology and bioinformatics have lifted the veil of uncertainty.

Provides insight into patient’s metabolic response
Surer, safer and selective drug therapy
Avoids Overdose / Underdose
Minimizes Adverse Drug Reactions (ADR)
Eliminates trial and error in therapy
Optimises therapeutic response
Affordable and once-in a-lifetime cost
Protects doctor from medicolegal complications

[/vc_column_text][/mkdf_tabs_item][mkdf_tabs_item tab_title=”Personal Genome Analysis”][vc_column_text css=”.vc_custom_1590680905955{margin-top: -20px !important;}”]

Personal Genome Analysis

[/vc_column_text][vc_single_image image=”11534″ alignment=”center”][vc_column_text]

INTRODUCTION

What can your DNA speak about your Health?

Human body cells have DNA, which influences many characteristics of the organism such as physical characteristics like height, colour of eyes, texture and colour of hair, etc. Human DNA encodes information for the processes that govern development, functioning and reproduction.

Gene represents certain specific stretches of DNA that are inherited from biological parents. These genes help to relate the characteristics of our parents and grandparents with us. They are the building blocks and everyone is born with a unique set of genes.

Datar Cancer Genetics Limited currently offers Personal Genome Analysis (PGA), which is a genetic test can analyse each pair of genes and identify changes in chromosomes or genes. These tests are called predictive tests, diagnostic tests, carrier tests and pharmacogenetic tests, based on their purpose. It is a modern genetic screening test that is performed on the DNA obtained from a person’s blood & saliva.

Determination of the disease predisposition of an individual
Determination of genetic makeup of an individual
Understand the impact of genes on diseases or conditions
DNA sequence and gives information about the disease or conditions

Provides insight into patient’s metabolic response
Surer, safer and selective drug therapy
Avoids Overdose / Underdose
Minimizes Adverse Drug Reactions (ADR)
Eliminates trial and error in therapy
Optimises therapeutic response
Affordable and once-in a-lifetime cost
Protects doctor from medicolegal complications

[/vc_column_text][/mkdf_tabs_item][mkdf_tabs_item tab_title=”Screengene”][vc_column_text css=”.vc_custom_1590680921877{margin-top: -20px !important;}”]

Screengene

[/vc_column_text][vc_single_image image=”11533″ img_size=”medium” alignment=”center”][vc_column_text]

INTRODUCTION

Hereditary Cancer Syndromes are caused by faulty changes in genes called as “Hereditary Mutations”. These can be passed down from parent to child and cause cancer to run in the family, making it Hereditary Cancer.

Simultaneous analysis of multiple cancer predisposition genes
More time and cost-effective than single gene testing for patients suspicious for multiple hereditary cancer syndromes
A greater likelihood of identifying a hereditary cause for cancer
Avoidance of false negative assurance given by limited genetic screening, which can miss risk-causing genetic mutations in other genes
A complete diagnostic work-up in a timely fashion without multiple follow-up visits for additional test results

Provides insight into patient’s metabolic response
Surer, safer and selective drug therapy
Avoids Overdose / Underdose
Minimizes Adverse Drug Reactions (ADR)
Eliminates trial and error in therapy
Optimises therapeutic response
Affordable and once-in a-lifetime cost
Protects doctor from medicolegal complications

[/vc_column_text][/mkdf_tabs_item][/mkdf_tabs][/vc_column][/vc_row]

Menu

Adhesive Dentistry

Specialty Clinics

Maxillofacial Care

Exacta

INTRODUCTION

About Exacta

Features of Exacta

TruBlood

INTRODUCTION

Cancer Track

INTRODUCTION

Gliotrack

INTRODUCTION

Liquid Biopsy For Lung Cancer

INTRODUCTION

Geneshield

INTRODUCTION

Personal Genome Analysis

INTRODUCTION

What can your DNA speak about your Health?

Screengene

INTRODUCTION